GMAB compared with NUVL: revenue, margins and what each company keeps, and the suppliers and customers both name

GMABGenmab A/S

Mkt capRevenueRevenue

NUVLNuvalent, Inc.

Mkt capRevenueRevenue

Compare

GMABGenmab A/S

NUVLNuvalent, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

GMABGenmab A/S

57.03▲+0.96%· post 57.15

Mkt cap$36.7B

NUVLNuvalent, Inc.

123.96▲+0.02%· post 123.96

ClosedOct 30 '26

Mkt cap$9.8B

Compare

ClosedOct 30 '26

GMABGenmab A/S

NUVLNuvalent, Inc.

57.03▲+0.96%post 57.15

Price

123.96▲+0.02%post 123.96

$36.7B

Mkt cap

$9.8B

GMAB57.03▲+0.96%vsNUVL123.96▲+0.02%ClosedOct 30 '26

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

rebased to 0%

GMAB, solidNUVL, dashed

Supply-chain overlap

Revenue flow

GMAB: latest quarter not drawable. NUVL: latest quarter not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only GMAB 1

COAGHemab Therapeuticscustomer

Shared 0

No disclosed counterparties: NUVL.

Only NUVL 0

None

Role chip = supplier or customerSource: SEC EDGAR